Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 1.12B |
| Revenue (ttm) | 186.37M |
| Net Income (ttm) | -163.42M |
| Shares Out | 46.61M |
| EPS (ttm) | -4.00 |
| PE Ratio | n/a |
| Forward PE | 104.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,068 |
| Open | 24.93 |
| Previous Close | 24.42 |
| Day's Range | 23.85 - 24.93 |
| 52-Week Range | 23.29 - 35.56 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 53.40 (+122.41%) |
| Earnings Date | May 2, 2024 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2023, MIRM's revenue was $186.37 million, an increase of 141.85% compared to the previous year's $77.06 million. Losses were -$163.42 million, 20.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is $53.4, which is an increase of 122.41% from the latest price.
News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome.
US FDA approves expanded use of Mirum's liver disease drug
The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company sa...
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pfic--Mirum's LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the...
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024.
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #leadership--Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer.
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates.
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia.
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Presents New Data at The Liver Meeting®.
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference.
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update.
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Present New Data at The Liver Meeting®.
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023.
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN.
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #cerebrotendinousxanthomatosis--Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xant...
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting.
Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference.
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer.
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Thera...
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update.